MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry
MindBio scientist’s sleep research published in prestigious peer reviewed scientific journalMindBio’s proprietary treatment protocol using MB22001, results in longer sleep and better quality of sleep the day after microdosing VANCOUVER, …
MindBio scientist’s sleep research published in prestigious peer reviewed scientific journal
MindBio’s proprietary treatment protocol using MB22001, results in longer sleep and better quality of sleep the day after microdosing
VANCOUVER, BC / ACCESSWIRE / April 23, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a clinical stage biopharma company uniquely pioneering novel treatments for psychiatric conditions using microdoses of psychedelic medicines is pleased to announce publication of its scientist's sleep research in the prestigious Nature portfolio journal Translational Psychiatry.
MindBio's unique investment thesis in the sector, is that small, sub-hallucinogenic doses of a psychedelic drug, MB22001 is the most scalable way to use a psychedelic medicine to treat depressive disorders globally. The Company's goal is to commercialize MB22001 as an affordable, accessible replacement to first line medications such as anti-depressants with low side effects (particularly no sexual side effects, emotional numbness, or weight gain) resulting in greater adherence to the treatment.
Lesen Sie auch
The sleep research accepted for publication is transformative for the treatment of depressive disorders because of the importance of sleep for maintaining good physical and mental well-being. We now know that MB22001 has a range of benefits for improving mood, energy, sleep and reducing depressive symptoms in patients suffering from depression. The sleep research from randomized controlled clinical trials, discovered participants in the treatment (MB22001) group had on average 24 minutes of extra sleep time and 8 minutes of additional REM sleep time the day after microdosing MB22001 compared to placebo in a one day on, two day off treatment protocol. Interestingly, sleep on dose days was not changed with no material difference between the treatment and placebo groups. The Company is now not only targeting depression in it's commercialization strategy for MB22001, but also addressing the adjacent negative impact on sleep commonly experienced in depression noting that the sleeping aids market is projected to reach $118 billion in 2030 according to research published by Polaris Market Research in 2022.